Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences announced the grant of stock options and restricted stock units to five new employees. A total of 8,200 shares can be purchased at an exercise price of $31.00, the closing price on December 8, 2022. Additionally, 4,100 restricted stock units were granted. These awards are part of the company’s 2020 Inducement Plan, approved in January 2020. Arcus Biosciences focuses on developing innovative cancer therapies and has expedited six investigational medicines into clinical studies.

Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced positive results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line metastatic non-small cell lung cancer (NSCLC). The analysis, conducted with a data cutoff on August 31, 2022, included 150 patients and demonstrated that both domvanalimab combinations significantly outperformed zimberelimab monotherapy across multiple efficacy measures, including progression-free survival (PFS). Results will be presented at the ASCO Monthly Plenary Series on December 20, 2022.

Gilead Sciences and Arcus Biosciences announced promising results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line NSCLC patients. The study evaluates the effects of domvanalimab (anti-TIGIT) in combination with zimberelimab (anti-PD-1) versus zimberelimab alone. Results indicate significant clinical benefits across key efficacy measures, including progression-free survival (PFS). No unexpected safety issues were noted. Full results will be presented on December 20, 2022, at the ASCO Monthly Plenary Series.

Arcus Biosciences (NYSE:RCUS) will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 11:20 a.m. Eastern Time. Investors can access the live webcast via the Investors & Media section of their website. Arcus is focused on developing innovative treatments for cancer, collaborating with global partners to expedite the development of first- or best-in-class medicines. Since its founding in 2015, Arcus has initiated clinical studies for six investigational medicines targeting critical pathways in cancer treatment.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to nine new employees. A total of 13,700 options were granted at an exercise price of $24.69, the closing price on November 8, 2022, alongside 6,850 restricted stock units. These awards were made under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus focuses on developing innovative cancer therapies through clinical studies on various investigational medicines targeting key biological pathways.

Arcus Biosciences reported its Q3 2022 financial results, revealing revenues of $33.6 million, up from $9.5 million in Q3 2021, driven by collaboration with Gilead. The company holds $1.2 billion in cash, sufficient to fund operations into 2026. Arcus is advancing its clinical pipeline, focusing on anti-TIGIT therapies with three Phase 3 trials for domvanalimab in lung cancer. A strategic amendment to the ARC-10 trial design now compares domvanalimab and zimberelimab to pembrolizumab, excluding a chemotherapy arm. The trial aims to define a new standard-of-care in NSCLC.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of options and restricted stock units to 14 new employees, totaling 35,200 shares at an exercise price of $26.15, the closing price on October 10, 2022. Additionally, 17,600 shares were awarded as restricted stock units. This award is part of the company’s 2020 Inducement Plan, which complies with NYSE regulations. Arcus focuses on developing innovative cancer therapies and has advanced six investigational medicines to clinical studies.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to ten new employees, totaling 33,950 and 16,975 shares, respectively. The options were priced at $25.70, aligning with the closing price on September 8, 2022. This equity grant falls under the 2020 Inducement Plan, approved by the Board of Directors. Arcus is focused on developing innovative cancer therapies, with clinical studies underway for six investigational medicines targeting various biological pathways.

Arcus Biosciences (NYSE:RCUS) announced its participation in key investor conferences. The Citi 17th Annual BioPharma Conference will take place on September 7, 2022, in Boston, MA, featuring 1-on-1 meetings. Following this, the Morgan Stanley 20th Annual Global Healthcare Conference is scheduled for September 12, 2022, in New York, NY, with a fireside chat at 12:30 p.m. ET. A live webcast will be available on the Arcus website, with replays accessible afterward.